Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention

Depression is associated with increased risk of primary and secondary cardiovascular events. Medication adherence may play an essential role. To evaluate the association of depression and 12-month adherence to guideline-directed medical therapies (eg, antiplatelet agents, β-blockers, renin-angiotens...

Full description

Saved in:
Bibliographic Details
Published in:JAMA network open 2022-12, Vol.5 (12), p.e2246317-e2246317
Main Authors: Lapa, Matthew E, Swabe, Gretchen M, Rollman, Bruce L, Muldoon, Matthew F, Thurston, Rebecca C, Magnani, Jared W
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Aged
Angioplasty
Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Cohort analysis
Cohort Studies
Endocrine system
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Intervention
Male
Mental depression
Patient compliance
Percutaneous Coronary Intervention
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Depression is associated with increased risk of primary and secondary cardiovascular events. Medication adherence may play an essential role. To evaluate the association of depression and 12-month adherence to guideline-directed medical therapies (eg, antiplatelet agents, β-blockers, renin-angiotensin-aldosterone system inhibitors [ie, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers], and statins) following percutaneous coronary intervention. This retrospective cohort study included individuals who underwent percutaneous coronary intervention from January 1, 2014, to December 31, 2019. Data were collected from a large US health claims database and analyzed between February and August 2022. Proportion of days covered (PDC) for classes of guideline-directed medical therapies, with 12-month adherence categorized as adequate (PDC ≥80% to
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2022.46317